IVD Medical (華檢醫療) IPO Review - More than 70% of IPO Proceeds Used for Dividend and Acquisition

APAC IPOs & Placements

Zhen Zhou, Toh

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

<p><a href="https://www.smartkarma.com/entities/ivd-medical-holding-ltd" target="_blank" data-smartkarma-citation="entities:28143:1" rel="noopener">IVD Medical (1931 HK)</a> raised US$131m at HK$3.07 per share, the bottom end of its IPO price range. We have previously covered the IPO in our note:</p><ul><li>
<a href="https://www.smartkarma.com/insights/ivd-medical-ipo-review-more-than-70-of-ipo-proceeds-used-for-dividend-and-acquisition" target="_blank" data-smartkarma-citation="insights:30742" rel="noopener">IVD Medical (華檢醫療) IPO Review - More than 70% of IPO Proceeds Used for Dividend and Acquisition</a> </li></ul><p>In this insight, we will update on the deal dynamics, implied valuation, and include a valuation sensitivity table.</p>

IVD Medical (1931 HK) raised US$131m at HK$3.07 per share, the bottom end of its IPO price range. We have previously covered the IPO in our note:
IVD Medical (華檢醫療) IPO Review - More than 70% of IPO Proceeds Used for Dividend and Acquisition In this insight, we will update on the deal dynamics, implied valuation, and include a valuation sensitivity table.

China Tobacco International (HK) (6055 HK)

IVD Medical (華檢醫療) Trading Update - Concentrated Shareholding, Tiny Adjusted Free-Float